Keywords: control, cmv, retinitis, isis, drug, pharmaceuticals, reported
"Control" Of CMV Retinitis With Isis Drug
Article | 24 February 1997
Isis Pharmaceuticals has reported interim data from an ongoing PhaseIII trial which demonstrates that its antisense drug fomivirsen (ISIS 2922) has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
